Ignacio Duran

List of Publications by Citations

160 papers	6,538 citations	37 h-index	79 g-index
178 ext. papers	8,720 ext. citations	5.5 avg, IF	5.54 L-index

#	Paper	IF	Citations
160	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet, The*, **2017**, 389, 67-76	40	1171
159	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet, The*, **2018**, 391, 748-757	40	753
158	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *New England Journal of Medicine*, **2019**, 381, 338-348	59.2	456
157	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 1370-1385	21.7	343
156	A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. *British Journal of Cancer*, **2006**, 95, 1148-54	8.7	272
155	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. *Nature Medicine*, **2019**, 25, 1706-1714	50.5	193
154	Biomarkers of response to PD-1/PD-L1 inhibition. *Critical Reviews in Oncology/Hematology*, **2017**, 116, 116-124	7	185
153	Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. *Annals of Oncology*, **2017**, 28, 1508-1516	10.3	166
152	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *European Urology*, **2020**, 77, 508-547	10.2	155
151	Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. *European Journal of Cancer*, **2006**, 42, 1875-80	7.5	131
150	Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. *European Urology*, **2015**, 67, 740-9	10.2	129
149	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 1574-1588	21.7	115
148	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *New England Journal of Medicine*, **2021**, 384, 1125-1135	59.2	110
147	Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. *Journal of Clinical Oncology*, **2008**, 26, 1940-7	2.2	109
146	Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. *Journal of Clinical Oncology*, **2011**, 29, 1750-6	2.2	101
145	Solution of the quasi-one-dimensional linearized Euler equations using flow invariants and the Magnus expansion. *Journal of Fluid Mechanics*, **2013**, 723, 190-231	3.7	92
144	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). *Annals of Oncology*, **2015**, 26, 1987-1993	10.3	85

143	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. *European Journal of Cancer*, **2014**, 50, 3145-52	7.5	82
142	Systemic treatment of renal cell cancer: A comprehensive review. *Cancer Treatment Reviews*, **2017**, 60, 77-89	14.4	81
141	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection **2017**, 5, 71		77
140	Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. *European Urology*, **2011**, 59, 556-62	10.2	75
139	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. *European Urology*, **2019**, 76, 73-81	10.2	74
138	Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). *European Journal of Cancer*, **2013**, 49, 3780-7	7.5	74
137	Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. *Clinical Cancer Research*, **2007**, 13, 4849-57	12.9	74
136	Chromophobe renal cell carcinoma: a review of an uncommon entity. *International Journal of Urology*, **2012**, 19, 894-900	2.3	67
135	Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. *Cancer*, **2004**, 100, 2462-9	6.4	63
134	A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).. *Journal of Clinical Oncology*, **2018**, 36, 4506-4506	2.2	62
133	Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. *Journal of Neuro-Oncology*, **2004**, 66, 345-50	4.8	60
132	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. *Targeted Oncology*, **2017**, 12, 19-35	5	57
131	A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) **2019**, 7, 20		50
130	Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. *Investigational New Drugs*, **2009**, 27, 586-94	4.3	50
129	Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. *Journal of Medical Economics*, **2013**, 16, 691-700	2.4	46
128	Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. *Anti-Cancer Drugs*, **2010**, 21, 478-86	2.4	45
127	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).. *Journal of Clinical Oncology*, **2018**, 36, 4503-4503	2.2	42
126	A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. *European Urology*, **2014**, 65, 516-20	10.2	41

125	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). *Critical Reviews in Oncology/Hematology*, **2020**, 151, 102978	7	39
124	Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. *Cancer Treatment Reviews*, **2012**, 38, 767-75	14.4	37
123	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. *Cancer*, **2020**, 126, 1208-1216	6.4	37
122	Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries. *Journal of Bone Oncology*, **2014**, 3, 40-8	4.5	36
121	Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. *Journal of General Internal Medicine*, **2006**, 21, C6-8	4	30
120	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. *Expert Opinion on Drug Safety*, **2014**, 13, 361-72	4.1	26
119	Immunotherapy in prostate cancer: review of the current evidence. *Clinical and Translational Oncology*, **2015**, 17, 339-57	3.6	25
118	SEOM clinical guidelines for the treatment of renal cell carcinoma. *Clinical and Translational Oncology*, **2014**, 16, 1043-50	3.6	24
117	Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. *European Urology*, **2020**, 77, 269-276	10.2	24
116	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. *European Urology*, **2018**, 73, 462-468	10.2	23
115	Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.. *Journal of Clinical Oncology*, **2018**, 36, 409-409	2.2	22
114	Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.. *Journal of Clinical Oncology*, **2018**, 36, 411-411	2.2	21
113	DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.. *Journal of Clinical Oncology*, **2020**, 38, 5012-5012	2.2	21
112	New drug development in digestive neuroendocrine tumors. *Annals of Oncology*, **2007**, 18, 1307-13	10.3	18
111	Simulation and modelling of the waves transmission and generation in a stator blade row in a combustion-noise framework. *Journal of Sound and Vibration*, **2014**, 333, 6090-6106	3.9	17
110	Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours. *Clinical and Translational Oncology*, **2014**, 16, 322-9	3.6	16
109	Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. *Molecular Cancer Therapeutics*, **2010**, 9, 751-60	6.1	16
108	Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel -Activating Mutation. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 1310-1315	7.3	13

107	Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.. *Journal of Clinical Oncology*, **2016**, 34, LBA4500-LBA4500	2.2	13
106	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. *Journal of Clinical Oncology*, **2021**, 39, 1553-1562	2.2	13
105	Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. *International Journal of Cancer*, **2018**, 143, 1954-1962	7.5	13
104	Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study. *European Journal of Cancer Care*, **2017**, 26, e12452	2.4	12
103	Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. *SpringerPlus*, **2014**, 3, 328		12
102	Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. *European Urology*, **2021**, 80, 7-11	10.2	12
101	Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer. *Clinical Pharmacokinetics*, **2020**, 59, 1135-1148	6.2	11
100	Expression of EGFR, HER-2/neu and KIT in germ cell tumours. *Clinical and Translational Oncology*, **2010**, 12, 443-9	3.6	11
99	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. *Journal of Urology*, **2020**, 204, 63-70	2.5	11
98	697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE). *Annals of Oncology*, **2020**, 31, S550-S551	10.3	11
97	The continuing role of chemotherapy in the management of advanced urothelial cancer. *Therapeutic Advances in Urology*, **2018**, 10, 455-480	3.2	11
96	EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).. *Journal of Clinical Oncology*, **2019**, 37, TPS497-TPS497	2.2	10
95	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.. *Journal of Clinical Oncology*, **2020**, 38, 5015-5015	2.2	10
94	Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma. *Oncotarget*, **2017**, 8, 106551-106564	3.3	10
93	SEOM clinical guidelines for the management of germ cell testicular cancer (2016). *Clinical and Translational Oncology*, **2016**, 18, 1187-1196	3.6	9
92	Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation. *BMC Cancer*, **2018**, 18, 561	4.8	9
91	Dural metastases in advanced prostate cancer: a case report and review of the literature. *Current Urology*, **2013**, 7, 166-8	1.7	9
90	Non-clear cell advanced kidney cancer: is there a gold standard?. *Anti-Cancer Drugs*, **2011**, 22 Suppl 1, S9-14	2.4	9

89	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. *European Urology Oncology*, **2021**, 4, 464-472	6.7	9
88	Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Subgroup analysis from a prospective multinational study. *Molecular and Clinical Oncology* , **2014**, 2, 701-708	1.6	8
87	Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study. *Journal of Clinical Medicine*, **2014**, 3, 883-96	5.1	8
86	Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors. *Acta Oncologica*, **2009**, 48, 475-7	3.2	8
85	Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer. *Clinical and Translational Oncology*, **2019**, 21, 796-804	3.6	8
84	Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	7
83	Biological markers of cisplatin resistance in advanced testicular germ cell tumours. *Clinical and Translational Oncology*, **2012**, 14, 452-7	3.6	7
82	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.. *Lancet Oncology, The*, **2022**,	21.7	7
81	Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study. *European Journal of Haematology*, **2018**, 100, 479-487	3.8	6
80	PCN115 Cost of Skeletal-Related Events (SREs) in Patients with Bone Metastases to solid Tumours Based on the Health Resource Utilisation (HRU) Collected in a Prospective European Multinational Observational Study. *Value in Health*, **2011**, 14, A455	3.3	6
79	Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.. *Journal of Clinical Oncology*, **2020**, 38, 511-511	2.2	6
78	PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)NCT01280201.. *Journal of Clinical Oncology*, **2012**, 30, 4119-4119	2.2	5
77	Phase II study of dovitinib in first line metastatic or (nonresectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03.. *Journal of Clinical Oncology*, **2013**, 31, 4587-4587	2.2	5
76	Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03.. *Journal of Clinical Oncology*, **2014**, 32, 4588-4588	2.2	5
75	Response to systemic therapy in non-clear cell renal cell carcinomas: A systematic review and meta-analysis.. *Journal of Clinical Oncology*, **2014**, 32, 425-425	2.2	5
74	DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.. *Journal of Clinical Oncology*, **2019**, 37, TPS4588-TPS4588	2.2	5
73	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.. *Lancet Oncology, The*, **2022**,	21.7	5
72	Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).. *Journal of Clinical Oncology*, **2021**, 39, 4576-4576	2.2	5

71	SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. *Pharmacogenomics*, **2016**, 17, 463-71	2.6	5
70	Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.. *Journal of Clinical Oncology*, **2021**, 39, 393-393	2.2	5
69	The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges. *Expert Review of Anticancer Therapy*, **2017**, 17, 217-226	3.5	4
68	Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib. *OncoTargets and Therapy*, **2017**, 10, 4885-4893	4.4	4
67	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. *European Urology Oncology*, **2021**, 4, 456-463	6.7	4
66	PCN76 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE: ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY. *Value in Health*, **2011**, 14, A168	3.3	3
65	Mixed paratesticular liposarcoma with osteosarcoma elements. *Clinical and Translational Oncology*, **2010**, 12, 148-9	3.6	3
64	Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer. *British Journal of Cancer*, **2007**, 96, 178-179	8.7	3
63	Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. *Anti-Cancer Drugs*, **2006**, 17, 81-7	2.4	3
62	Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)Interim analysis on safety.. *Journal of Clinical Oncology*, **2014**, 32, 359-359	2.2	3
61	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. *BJU International*, **2021**, 128, 196-205	5.6	3
60	Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience. *Clinical and Translational Oncology*, **2017**, 19, 173-179	3.6	2
59	MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 640.e23-640.e29	2.8	2
58	Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective. *Annals of Oncology*, **2017**, 28, v303	10.3	2
57	Disseminated intravascular coogulation as the presenting sign of metastatic prostate cancer. *Journal of General Internal Medicine*, **2006**, 21, 1206-1206	4	2
56	Prognostic significance of thromboembolic events in chemotherapy-treated germ cell tumors.. *Journal of Clinical Oncology*, **2015**, 33, 4536-4536	2.2	2
55	Everolimus as second-line treatment in metastatic renal cell carcinoma (mRCC) after first-line pazopanib (The RESCUE study): A retrospective analysis by the Hellenic GU Cancer Group (HGUCG) with international collaboration.. *Journal of Clinical Oncology*, **2015**, 33, e15601-e15601	2.2	2
54	Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.. *Journal of Clinical Oncology*, **2016**, 34, LBA4500-LBA4500	2.2	2

53	Pharmacokinetic food-effect study of abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC): The ABIFOOD trial (EudraCt number: 2012-003226-25).. *Journal of Clinical Oncology*, **2016**, 34, 227-227	2.2	2
52	Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2019**, 37, 550-550	2.2	2
51	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. *Expert Review of Molecular Diagnostics*, **2021**, 21, 1165-1178	3.8	2
50	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. *European Urology*, **2022**,	10.2	2
49	Phase I study of carboplatin in combination with PM00104 (Zalypsis) in patients with advanced solid tumors. *Investigational New Drugs*, **2014**, 32, 644-52	4.3	1
48	Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: case report and review of the literature. *World Journal of Surgical Oncology* , **2009**, 7, 96	3.4	1
47	Eyelid metastasis from mediastinal teratoma with malignant transformation. *Acta Oncologica*, **2007** , 46, 1200-1	3.2	1
46	JEVTCC: Phase II trial of cabazitaxel (Cbz) in patients (pt) with advanced or metastatic transitional-cell carcinoma (mTCC), who progressed before 12 months after cisplatin-based chemotherapy A Spanish Oncologic Genitourinary Group (SOGUG) study.. *Journal of Clinical*	2.2	1
45	Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatment ABIDO-SOGUG Trial.. *Journal of Clinical Oncology*, **2015**, 33, e16022-e16022	2.2	1
44	Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.. *Journal of Clinical Oncology*, **2015**, 33, 167-167	2.2	1
43	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.. *Journal of Clinical Oncology*, **2017**, 35, 323-323	2.2	1
42	The role of microRNAs (miRNAs) as predictive biomarker in advanced renal cell carcinoma (mRCC) patients (pts) with extreme response to tyrosine kinase inhibitors (TKIs) treatment.. *Journal of Clinical Oncology*, **2017**, 35, 470-470	2.2	1
41	The application of cognitive computing technology in genomics in precision oncological medicine: The Sistemas Genomicos Experience.. *Journal of Clinical Oncology*, **2018**, 36, e18544-e18544	2.2	1
40	Interim analysis of ibrutinib plus paclitaxel for patients with metastatic urothelial carcinoma previously treated with platinum-based chemotherapy.. *Journal of Clinical Oncology*, **2019**, 37, 365-365	2.2	1
39	Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.. *Journal of Clinical Oncology*, **2020**, 38, 3055-3055	2.2	1
38	A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naïve metastatic castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 5040-5040	2.2	1
37	Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. *Journal of Urology*, **2019**, 202, 742-747	2.5	1
36	Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. *Clinical and Translational Oncology*, **2021**, 23, 58-64	3.6	1

35	Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. *Clinical and Translational Oncology*, **2021**, 23, 882-891	3.6	1
34	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.. *Clinical Genitourinary Cancer*, **2021**,	3.3	1
33	Gold Glyconanoparticles Combined with 91□99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder Tumors. *Cancers*, **2022**, 14, 2413	6.6	1
32	Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. *European Urology Open Science*, **2020**, 21, 61-68	0.9	0
31	Treatment efficacy of abiraterone (abi), enzalutamide (enza) or cabazitaxel (caba) in metastasic castration-resistant prostate cancer patients (mCRPC) after progression to docetaxel plus androgen deprivation therapy (ADT) in hormone sensible disease.. *Journal of Clinical Oncology*, **2019**, 37, 198-198	2.2	0
30	Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.. *Journal of Clinical Oncology*, **2020**, 38, 95-95	2.2	0
29	Quality of life assessment in patients with advanced renal cancer: CAVIREN study.. *Journal of Clinical Oncology*, **2015**, 33, e20654-e20654	2.2	0
28	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. *European Urology Focus*, **2021**, 7, 1084-1091	5.1	0
27	Recent Therapeutic Advances in Urothelial Carcinoma: A Paradigm Shift in Disease Management.. *Critical Reviews in Oncology/Hematology*, **2022**, 103683	7	0
26	An□lisis del impacto presupuestario de denosumab para la prevenci□ de eventos relacionados con el esqueleto en adultos con met□stasis □seas de tumores s□dos en Espa□a. *Pharmacoeconomics - Spanish Research Articles*, **2015**, 12, 83-92		
25	Nuevos tratamientos en los tumores neuroendocrinos gastroenteropancre□icos. *Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion*, **2007**, 54, 51-57		
24	MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue.. *Journal of Clinical Oncology*, **2020**, 38, 541-541	2.2	
23	ECO Experts□consensus on establishing renal cancer healthcare quality measures in Spain.. *Journal of Clinical Oncology*, **2020**, 38, 220-220	2.2	
22	Immunotherapy and New Combinations in Muscle-Invasive Bladder Cancer **2018**, 91-98		
21	A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.. *Journal of Clinical Oncology*, **2018**, 36, TPS4593-TPS4593	2.2	
20	A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.. *Journal of Clinical Oncology*, **2019**, 37, TPS501-TPS501	2.2	
19	FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis.. *Journal of Clinical Oncology*, **2019**, 37, 411-411	2.2	
18	Interim analysis of ibrutinib plus paclitaxel for patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy.. *Journal of Clinical Oncology*, **2019**, 37, 4522-4522	2.2	

17	Single nucleotide polymorphisms (SNPs) as predictors of efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2020**, 38, e17582-e17582	2.2
16	Expert consensus on the development of quality care measures for kidney cancer in Spain.. *Journal of Clinical Oncology*, **2020**, 38, e19180-e19180	2.2
15	Preliminary circulating tumour cell (CTC) analysis in phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel treatment (SOGUG-CABASEM trial).. *Journal of Clinical Oncology*, **2014**, 32, e16034-e16034	2.2
14	Randomized phase II study of abiraterone acetate maintenance in combination with docetaxel after disease progression to abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC): ABIDO SOGUG trial.. *Journal of Clinical Oncology*, **2014**, 32, TPS5096-TPS5096	2.2
13	Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy: PREMIERE-SOGUG Trial.. *Journal of Clinical Oncology*, **2015**, 33, TPS5073-TPS5073	2.2
12	Safety of cabazitaxel (Cbz) in patients (pt) with metastatic transitional-cell carcinoma (mTCC) progressing to cisplatin-based chemotherapy: Results from the JEVTCC-SOGUG Study.. *Journal of Clinical Oncology*, **2015**, 33, e15537-e15537	2.2
11	Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial.. *Journal of Clinical Oncology*, **2016**, 34, 5058-5058	2.2
10	Phase II study of pazopanib plus interferon alfa as first-line therapy of advanced renal cell carcinoma: A Spanish Oncology Genitourinary Group (SOGUG) study.. *Journal of Clinical Oncology*, **2016**, 34, 4571-4571	2.2
9	Neuroendocrine Carcinoma **2017**, 3052-3057	
8	Single-nucleotide polymorphisms (SNPs) associated with outcomes in patients with localized and metastatic renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, 437-437	2.2
7	Neuroendocrine Carcinoma **2011**, 2482-2486	
6	Retrospective study for the characterization of COVID-19 in renal cancer (COVID-REN) patients treated with antiangiogenics or immunotherapy and outcome comparison with non-infected cases.. *Journal of Clinical Oncology*, **2021**, 39, 4577-4577	2.2
5	Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).. *Journal of Clinical Oncology*, **2021**, 39, e16555-e16555	2.2
4	Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).. *Journal of Clinical Oncology*, **2021**, 39, 336-336	2.2
3	Immune characterization of urothelial bladder carcinoma integrating transurethral resection of bladder tumor (TURBT) samples and serum: A feasibility study.. *Journal of Clinical Oncology*, **2022**, 40, 538-538	2.2
2	Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab ± ipilimumab in the TITAN-RCC phase 2 trial.. *Journal of Clinical Oncology*, **2022**, 40, 367-367	2.2
1	Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.. *Journal of Clinical Oncology*, **2022**, 40, 490-490	2.2